Search by Algolia
Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
GUARANTY BANCSHARES INC /TX/Guaranty Bancshares Reports $3.12 Billion in Total Assets and $31.5 Million Net Earnings for 2024
Oxford Square Capital Corp.Oxford Square Capital Corp. Reports $26.4 Million Net Investment Income for Fiscal Year 2024
Teucrium Commodity TrustTeucrium Commodity Trust Reports $47.86 Million Net Loss for 2024
Vroom, Inc.Vroom, Inc. Reports $165.1 Million Net Loss for 2024, Emerges from Chapter 11 Bankruptcy
Summit Midstream CorpSummit Midstream Corporation Reports $113.175 Million Net Loss for 2024
Owlet, Inc.Owlet Reports $12.5 Million Net Loss in 2024, Revenue Increases 44.5%
Third Coast Bancshares, Inc.Third Coast Bancshares Reports 42.7% Increase in Net Income to $47.67 Million for 2024
TriplePoint Venture Growth BDC Corp.TriplePoint Venture Growth BDC Reports $32M Net Increase in Assets for 2024
GRAIL, Inc.GRAIL Reports $2.027 Billion Net Loss and 35% Revenue Growth for Fiscal Year 2024
Editas Medicine, Inc.Editas Medicine Reports $237.1 Million Net Loss for 2024, Revenue Declines to $32.3 Million
Lyell Immunopharma, Inc.Lyell Immunopharma Reports $342.99 Million Net Loss and Acquires ImmPACT Bio USA Inc.
Verrica Pharmaceuticals Inc.Verrica Pharmaceuticals Reports $76.6 Million Net Loss for 2024, Increased Product Revenue
Mural Oncology plcMural Oncology Reports $128.5 Million Net Loss for 2024, Decreased R&D Expenses
Tvardi Therapeutics, Inc.Cara Therapeutics Reports $70.9 Million Net Loss for 2024, Revenue Declines to $7.1 Million
WEBTOON Entertainment Inc.WEBTOON Entertainment Reports $152.9 Million Net Loss Despite 5.1% Revenue Growth
Dianthus Therapeutics, Inc. /DE/Dianthus Therapeutics Reports $84.97 Million Net Loss and $6.24 Million Revenue for 2024
Zymeworks Inc.Zymeworks Reports $122.7 Million Net Loss for 2024, Revenue Increases to $76.3 Million
Voyager Therapeutics, Inc.Voyager Therapeutics Reports $65M Net Loss and $80M Revenue for 2024
Astria Therapeutics, Inc.Astria Therapeutics Reports $94.26 Million Net Loss for 2024, Driven by Increased R&D Expenses
FATE THERAPEUTICS INCFate Therapeutics Reports $186.2 Million Net Loss for Fiscal Year 2024
ORTHOPEDIATRICS CORPOrthoPediatrics Reports 38% Revenue Growth to $204.7 Million, Net Loss of $37.8 Million for 2024
Blend Labs, Inc.Blend Labs Reports $43.4 Million Net Loss and 3% Revenue Increase for 2024
SUTRO BIOPHARMA, INC.Sutro Biopharma Reports $227.4 Million Net Loss for 2024, Revenue Decrease of 60%
Ascend Wellness Holdings, Inc.Ascend Wellness Holdings Reports $84.99 Million Net Loss Despite 8% Revenue Growth in 2024
ACTUATE THERAPEUTICS, INC.Actuate Therapeutics Reports $27.3 Million Net Loss for 2024, IPO Raises $22 Million